{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:04:00Z","timestamp":1789664640198,"version":"4.0.1"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40265-023-01856-x","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T14:02:51Z","timestamp":1679925771000},"page":"479-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-1228","authenticated-orcid":false,"given":"Chi Chiu","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"1856_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","volume":"28","author":"CC Mok","year":"2019","unstructured":"Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28:85\u201392.","journal-title":"Expert Opin Investig Drugs"},{"key":"1856_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110\u201321.","journal-title":"N Engl J Med"},{"key":"1856_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fimmu.2016.00035","volume":"7","author":"A Mahajan","year":"2016","unstructured":"Mahajan A, Herrmann M, Mu\u00f1oz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016;7:35.","journal-title":"Front Immunol"},{"key":"1856_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649693","volume":"12","author":"M Fresneda Alarcon","year":"2021","unstructured":"Fresneda Alarcon M, McLaren Z, Wright HL. Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: Same foe different M.O. Front Immunol. 2021;12: 649693.","journal-title":"Front Immunol"},{"key":"1856_CR5","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","volume":"188","author":"J Leffler","year":"2012","unstructured":"Leffler J, Martin M, Gullstrand B, Tyd\u00e9n H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188:3522\u201331.","journal-title":"J Immunol"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1073\/pnas.0909927107","volume":"107","author":"A Hakkim","year":"2010","unstructured":"Hakkim A, F\u00fcrnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107:9813\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1856_CR7","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3389\/fimmu.2018.01957","volume":"9","author":"K Sakata","year":"2018","unstructured":"Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K, et al. Up-regulation of TLR7-mediated IFN-\u03b1 production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol. 2018;9:1957.","journal-title":"Front Immunol"},{"key":"1856_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1172\/JCI23025","volume":"115","author":"TK Means","year":"2005","unstructured":"Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Investig. 2005;115:407\u201317.","journal-title":"J Clin Investig"},{"key":"1856_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/art.37821","volume":"65","author":"ML Eloranta","year":"2013","unstructured":"Eloranta ML, Alm GV, R\u00f6nnblom L. Disease mechanisms in rheumatology\u2013tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheumatol. 2013;65:853\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/ar2966","volume":"12","author":"JH Fransen","year":"2010","unstructured":"Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther. 2010;12:207.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jaut.2010.06.018","volume":"35","author":"C Scheinecker","year":"2010","unstructured":"Scheinecker C, Bonelli M, Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 2010;35:269\u201375.","journal-title":"J Autoimmun"},{"issue":"Suppl 2","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"ii85","DOI":"10.1136\/annrheumdis-2012-202341","volume":"72","author":"K Fujio","year":"2013","unstructured":"Fujio K, Okamura T, Sumitomo S, Yamamoto K. Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Ann Rheum Dis. 2013;72(Suppl 2):ii85\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/jir.2011.0029","volume":"31","author":"SA Apostolidis","year":"2011","unstructured":"Apostolidis SA, Lieberman LA, Kis-Toth K, Crisp\u00edn JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:769\u201379.","journal-title":"J Interferon Cytokine Res"},{"key":"1856_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/347141","volume":"2012","author":"DL Su","year":"2012","unstructured":"Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012: 347141.","journal-title":"J Biomed Biotechnol"},{"key":"1856_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/ar3349","volume":"13","author":"N Jacob","year":"2011","unstructured":"Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:228.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2008;58:2453\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13075-021-02414-0","volume":"23","author":"L Mai","year":"2021","unstructured":"Mai L, Asaduzzaman A, Noamani B, Fortin PR, Gladman DD, Touma Z, et al. The baseline interferon signature predicts disease severity over the subsequent 5\u00a0years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23:29.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12920-018-0468-1","volume":"12","author":"M Petri","year":"2019","unstructured":"Petri M, Fu W, Ranger A, Allaire N, Cullen P, Magder LS, et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genom. 2019;12:4.","journal-title":"BMC Med Genom"},{"key":"1856_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13543784.2022.2040014","volume":"31","author":"S Tang","year":"2022","unstructured":"Tang S, Yu Q, Ding C. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Expert Opin Investig Drugs. 2022;31:291\u2013303.","journal-title":"Expert Opin Investig Drugs"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s40265-021-01592-0","volume":"81","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Rip J, Hendriks RW, Corneth OBJ. Bruton\u2019s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease. Drugs. 2021;81:1605\u201326.","journal-title":"Drugs"},{"key":"1856_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111646","volume":"182","author":"J Xi","year":"2019","unstructured":"Xi J, Zhuang R, Kong L, He R, Zhu H, Zhang J. Immunoproteasome-selective inhibitors: an overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182: 111646.","journal-title":"Eur J Med Chem"},{"key":"1856_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100994","volume":"57","author":"O Fuchs","year":"2023","unstructured":"Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023;57: 100994.","journal-title":"Blood Rev"},{"key":"1856_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","volume":"76","author":"HC Tsai","year":"2016","unstructured":"Tsai HC, Han MH. Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs. 2016;76:1067\u201379.","journal-title":"Drugs"},{"key":"1856_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-022-00784-6","volume":"18","author":"N Burg","year":"2022","unstructured":"Burg N, Salmon JE, Hla T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol. 2022;18:335\u201351.","journal-title":"Nat Rev Rheumatol"},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36:503\u201314.","journal-title":"Immunity"},{"key":"1856_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"1856_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58:953\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"1856_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161\u201370.","journal-title":"N Engl J Med"},{"key":"1856_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17:78.","journal-title":"Nat Rev Drug Discov"},{"key":"1856_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","volume":"104","author":"M Gadina","year":"2018","unstructured":"Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104:499\u2013514.","journal-title":"J Leukoc Biol"},{"key":"1856_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521\u201346.","journal-title":"Drugs"},{"key":"1856_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","volume":"148","author":"Y Luo","year":"2021","unstructured":"Luo Y, Alexander M, Gadina M, O\u2019Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol. 2021;148:911\u201325.","journal-title":"J Allergy Clin Immunol"},{"key":"1856_CR33","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.4049\/jimmunol.1101228","volume":"187","author":"LD Lu","year":"2011","unstructured":"Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol. 2011;187:3840\u201353.","journal-title":"J Immunol"},{"key":"1856_CR34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/0961203310367660","volume":"19","author":"S Wang","year":"2010","unstructured":"Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y, et al. Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice. Lupus. 2010;19:1171\u201380.","journal-title":"Lupus"},{"key":"1856_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","volume":"18","author":"\u00c8 Ripoll","year":"2016","unstructured":"Ripoll \u00c8, de Ramon L, DraibeBordignon J, Merino A, Bola\u00f1os N, Goma M, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18:134.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12865-017-0225-9","volume":"18","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18:41.","journal-title":"BMC Immunol"},{"key":"1856_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.46497\/ArchRheumatol.2022.8252","volume":"37","author":"J Lin","year":"2022","unstructured":"Lin J, Zhang Y, Wang M, Zhang Y, Li P, Cao Y, et al. Therapeutic effects of tofacitinib on pristane-induced murine lupus. Arch Rheumatol. 2022;37:195\u2013204.","journal-title":"Arch Rheumatol"},{"key":"1856_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","volume":"69","author":"Y Furumoto","year":"2017","unstructured":"Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. 2017;69:148\u201360.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675542","volume":"12","author":"Q Yan","year":"2021","unstructured":"Yan Q, Chen W, Song H, Long X, Zhang Z, Tang X, et al. Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-beta type I receptor. Front Immunol. 2021;12: 675542.","journal-title":"Front Immunol"},{"key":"1856_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704526","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, et al. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol. 2021;12: 704526.","journal-title":"Front Immunol"},{"key":"1856_CR41","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/0961203311409963","volume":"20","author":"M Kawasaki","year":"2011","unstructured":"Kawasaki M, Fujishiro M, Yamaguchi A, Nozawa K, Kaneko H, Takasaki Y, et al. Possible role of the JAK\/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus. 2011;20:1231\u20139.","journal-title":"Lupus"},{"key":"1856_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/jir.2016.0040","volume":"37","author":"A Goropev\u0161ek","year":"2017","unstructured":"Goropev\u0161ek A, Gorenjak M, Gradi\u0161nik S, Dai K, Holc I, Hojs R, et al. Increased levels of STAT1 protein in blood CD4 T cells from systemic lupus erythematosus patients are associated with perturbed homeostasis of activated CD45RA-FOXP3hi regulatory subset and follow-up disease severity. J Interferon Cytokine Res. 2017;37:254\u201368.","journal-title":"J Interferon Cytokine Res"},{"key":"1856_CR43","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2017-212794","volume":"77","author":"N Hagberg","year":"2018","unstructured":"Hagberg N, Joelsson M, Leonard D, Reid S, Eloranta ML, Mo J, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-\u03b3 production in T cells from patients with SLE. Ann Rheum Dis. 2018;77:1070\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR44","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/eji.201646872","volume":"47","author":"MR de la Varga","year":"2017","unstructured":"de la Varga MR, Rodr\u00edguez-Bayona B, A\u00f1ez GA, Medina Varo F, P\u00e9rez Venegas JJ, Brieva JA, et al. Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation. Eur J Immunol. 2017;47:1211\u20139.","journal-title":"Eur J Immunol"},{"key":"1856_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/08820139.2020.1752712","volume":"50","author":"JM Wang","year":"2021","unstructured":"Wang JM, Xu WD, Huang AF. Association of STAT4 Gene Rs7574865, Rs10168266 polymorphisms and systemic lupus erythematosus susceptibility: a meta-analysis. Immunol Investig. 2021;50:282\u201394.","journal-title":"Immunol Investig"},{"key":"1856_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13075-020-02276-y","volume":"22","author":"P Tangtanatakul","year":"2020","unstructured":"Tangtanatakul P, Thumarat C, Satproedprai N, Kunhapan P, Chaiyasung T, Klinchanhom S, et al. Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population. Arthritis Res Ther. 2020;22:185.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR47","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.39504","volume":"68","author":"ME Alarc\u00f3n-Riquelme","year":"2016","unstructured":"Alarc\u00f3n-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, S\u00e1nchez-Rodr\u00edguez E, et al. Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol. 2016;68:932\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.humimm.2013.04.034","volume":"74","author":"J Zheng","year":"2013","unstructured":"Zheng J, Yin J, Huang R, Petersen F, Yu X. Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody. Hum Immunol. 2013;74:986\u201392.","journal-title":"Hum Immunol"},{"key":"1856_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001323","volume":"7","author":"SA Chung","year":"2011","unstructured":"Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 2011;7: e1001323.","journal-title":"PLoS Genet"},{"key":"1856_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084450","volume":"8","author":"K Bolin","year":"2013","unstructured":"Bolin K, Sandling JK, Zickert A, J\u00f6nsen A, Sj\u00f6wall C, Svenungsson E, et al. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS\u00a0One. 2013;8: e84450.","journal-title":"PLoS\u00a0One"},{"key":"1856_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4049\/jimmunol.182.1.34","volume":"182","author":"SN Kariuki","year":"2009","unstructured":"Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol. 2009;182:34\u20138.","journal-title":"J Immunol"},{"key":"1856_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000336","volume":"6","author":"MK Crow","year":"2019","unstructured":"Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6: e000336.","journal-title":"Lupus Sci Med"},{"key":"1856_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"1856_CR54","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"1856_CR55","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12:3391.","journal-title":"Nat Commun"},{"key":"1856_CR56","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/0961203316640910","volume":"25","author":"L Kahl","year":"2016","unstructured":"Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 2016;25:1420\u201330.","journal-title":"Lupus"},{"key":"1856_CR57","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0961203315573347","volume":"24","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Layton M, Kahl L, Schifano L, Hachulla E, Machado D, et al. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015;24:648\u20139.","journal-title":"Lupus"},{"key":"1856_CR58","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384.","journal-title":"Lancet"},{"key":"1856_CR59","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 Randomized Clinical Trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"},{"key":"1856_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"1856_CR61","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"1856_CR62","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"1856_CR63","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1856_CR64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327\u201336.","journal-title":"Lancet Respir Med"},{"key":"1856_CR65","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222\u201331.","journal-title":"Lancet"},{"key":"1856_CR66","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","volume":"24","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner T, van Vollenhoven RF, Doria A, Jia B, Ross Terres JA, Silk ME, et al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24:112.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000424","volume":"7","author":"T D\u00f6rner","year":"2020","unstructured":"D\u00f6rner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med. 2020;7: e000424.","journal-title":"Lupus Sci Med"},{"key":"1856_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(22)02607-1.","journal-title":"Lancet"},{"key":"1856_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, Tanaka Y, Morand EF, Kalunian KC, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6.","journal-title":"Lancet"},{"key":"1856_CR70","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75:242\u201352.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR71","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14728214.2020.1822817","volume":"25","author":"E CarneroContentti","year":"2020","unstructured":"CarneroContentti E, Correale J. Bruton\u2019s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs. 2020;25:377\u201381.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1856_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9: 668131.","journal-title":"Front Cell Dev Biol"},{"key":"1856_CR73","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","volume":"151","author":"C Liang","year":"2018","unstructured":"Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, et al. The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem. 2018;151:315\u201326.","journal-title":"Eur J Med Chem"},{"key":"1856_CR74","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/molecules26164907","volume":"26","author":"D Zhang","year":"2021","unstructured":"Zhang D, Gong H, Meng F. Recent advances in BTK inhibitors for the treatment of inflammatory and autoimmune diseases. Molecules. 2021;26:4907.","journal-title":"Molecules"},{"key":"1856_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","volume":"10","author":"J Rip","year":"2019","unstructured":"Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OBJ. Toll-like receptor signaling drives Btk-mediated autoimmune disease. Front Immunol. 2019;10:95.","journal-title":"Front Immunol"},{"key":"1856_CR76","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1189\/jlb.0513307","volume":"95","author":"G L\u00f3pez-Herrera","year":"2014","unstructured":"L\u00f3pez-Herrera G, Vargas-Hern\u00e1ndez A, Gonz\u00e1lez-Serrano ME, Berr\u00f3n-Ruiz L, Rodr\u00edguez-Alba JC, Espinosa-Rosales F, et al. Bruton\u2019s tyrosine kinase: an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol. 2014;95:243\u201350.","journal-title":"J Leukoc Biol"},{"key":"1856_CR77","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1242\/jcs.071043","volume":"123","author":"HS Kuehn","year":"2010","unstructured":"Kuehn HS, R\u00e5dinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, et al. Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci. 2010;123:2576\u201385.","journal-title":"J Cell Sci"},{"key":"1856_CR78","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","volume":"8","author":"LS Quek","year":"1998","unstructured":"Quek LS, Bolen J, Watson SP. A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8:1137\u201340.","journal-title":"Curr Biol"},{"key":"1856_CR79","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","volume":"132","author":"M Shinohara","year":"2008","unstructured":"Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132:794\u2013806.","journal-title":"Cell"},{"key":"1856_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113329","volume":"217","author":"J Liu","year":"2021","unstructured":"Liu J, Chen C, Wang D, Zhang J, Zhang T. Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development. Eur J Med Chem. 2021;217: 113329.","journal-title":"Eur J Med Chem"},{"key":"1856_CR81","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","volume":"15","author":"BW Christensen","year":"2022","unstructured":"Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol. 2022;15:321\u201331.","journal-title":"Expert Rev Hematol"},{"key":"1856_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","volume":"27","author":"PA Thompson","year":"2018","unstructured":"Thompson PA, Burger JA. Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL). Expert Opin Investig Drugs. 2018;27:31\u201342.","journal-title":"Expert Opin Investig Drugs"},{"key":"1856_CR83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clim.2018.10.008","volume":"197","author":"SA Chalmers","year":"2018","unstructured":"Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol. 2018;197:205\u201318.","journal-title":"Clin Immunol"},{"key":"1856_CR84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","volume":"19","author":"YY Kim","year":"2017","unstructured":"Kim YY, Park KT, Jang SY, Lee KH, Byun JY, Suh KH, et al. HM71224, a selective Bruton\u2019s tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017;19:211.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR85","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","volume":"191","author":"AL Rankin","year":"2013","unstructured":"Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013;191:4540\u201350.","journal-title":"J Immunol"},{"key":"1856_CR86","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.38047","volume":"65","author":"P Mina-Osorio","year":"2013","unstructured":"Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, et al. Suppression of glomerulonephritis in lupus-prone NZB \u00d7 NZW mice by RN486, a selective inhibitor of Bruton\u2019s tyrosine kinase. Arthritis Rheumatol. 2013;65:2380\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR87","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-017-1500-0","volume":"20","author":"SA Chalmers","year":"2018","unstructured":"Chalmers SA, Wen J, Doerner J, Stock A, Cuda CM, Makinde HM, et al. Highly selective inhibition of Bruton\u2019s tyrosine kinase attenuates skin and brain disease in murine lupus. Arthritis Res Ther. 2018;20:10.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR88","doi-asserted-by":"publisher","first-page":"R243","DOI":"10.1186\/ar4086","volume":"14","author":"J Hutcheson","year":"2012","unstructured":"Hutcheson J, Vanarsa K, Bashmakov A, Grewal S, Sajitharan D, Chang BY, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther. 2012;14:R243.","journal-title":"Arthritis Res Ther"},{"key":"1856_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clim.2016.01.012","volume":"164","author":"AT Bender","year":"2016","unstructured":"Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski L, et al. Btk inhibition treats TLR7\/IFN driven murine lupus. Clin Immunol. 2016;164:65\u201377.","journal-title":"Clin Immunol"},{"key":"1856_CR90","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","volume":"202","author":"P Haselmayer","year":"2019","unstructured":"Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol. 2019;202:2888\u2013906.","journal-title":"J Immunol"},{"key":"1856_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10067-017-3717-3","volume":"37","author":"W Kong","year":"2018","unstructured":"Kong W, Deng W, Sun Y, Huang S, Zhang Z, Shi B, et al. Increased expression of Bruton\u2019s tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol. 2018;37:43\u20139.","journal-title":"Clin Rheumatol"},{"key":"1856_CR92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","volume":"5","author":"DJ Wallace","year":"2023","unstructured":"Wallace DJ, D\u00f6rner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open Rheumatol. 2023;5:38\u201348.","journal-title":"ACR Open Rheumatol"},{"key":"1856_CR93","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.41275","volume":"72","author":"S Cohen","year":"2020","unstructured":"Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES Study). Arthritis Rheumatol. 2020;72:1435\u201346.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR94","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.18632\/oncotarget.24310","volume":"9","author":"JC Byrd","year":"2018","unstructured":"Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9:13023\u201335.","journal-title":"Oncotarget"},{"key":"1856_CR95","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1835\u201346.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 1","key":"1856_CR96","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5086a","volume":"81","author":"R Li","year":"2022","unstructured":"Li R, Zhu X, Liu S, Zhang X, Xie C, Fu Z, et al. Orelabrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase (btk), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase Ib\/IIa dose-finding study. Ann Rheum Dis. 2022;81(Suppl. 1):210.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","volume":"7","author":"GM Deng","year":"2016","unstructured":"Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78.","journal-title":"Front Immunol"},{"key":"1856_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156063","volume":"11","author":"B Aouar","year":"2016","unstructured":"Aouar B, Kovarova D, Letard S, Font-Haro A, Florentin J, Weber J, et al. Dual role of the tyrosine kinase Syk in regulation of Toll-like receptor signaling in plasmacytoid dendritic cells. PLoS\u00a0One. 2016;11: e0156063.","journal-title":"PLoS\u00a0One"},{"key":"1856_CR99","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/rheumatology\/kes367","volume":"52","author":"V Kelly","year":"2013","unstructured":"Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1155\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"1856_CR100","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.27452","volume":"62","author":"GM Deng","year":"2010","unstructured":"Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheumatol. 2010;62:2086\u201392.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR101","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.23428","volume":"58","author":"FR Bahjat","year":"2008","unstructured":"Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheumatol. 2008;58:1433\u201344.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR102","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41927-021-00178-3","volume":"5","author":"CW Pohlmeyer","year":"2021","unstructured":"Pohlmeyer CW, Shang C, Han P, Cui ZH, Jones RM, Clarke AS, et al. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis. BMC Rheumatol. 2021;5:15.","journal-title":"BMC Rheumatol"},{"key":"1856_CR103","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jphs.2017.02.015","volume":"134","author":"M Kitai","year":"2017","unstructured":"Kitai M, Fukuda N, Ueno T, Endo M, Maruyama T, Abe M, et al. Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. J Pharmacol Sci. 2017;134:29\u201336.","journal-title":"J Pharmacol Sci"},{"key":"1856_CR104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/cei\/uxac096","volume":"211","author":"S Cho","year":"2022","unstructured":"Cho S, Jang E, Yoon T, Hwang H, Youn J. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2022;211:31\u201345.","journal-title":"Clin Exp Immunol"},{"key":"1856_CR105","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40262-022-01135-0","volume":"61","author":"R Matsukane","year":"2022","unstructured":"Matsukane R, Suetsugu K, Hirota T, Ieiri I. Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406. Clin Pharmacokinet. 2022;61:955\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"1856_CR106","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-021-01524-y","volume":"81","author":"J Paik","year":"2021","unstructured":"Paik J. Fostamatinib: a review in chronic immune thrombocytopenia. Drugs. 2021;81:935\u201343.","journal-title":"Drugs"},{"key":"1856_CR107","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.140238","volume":"41","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-\u03b1 antagonist. J Rheumatol. 2014;41:2120\u20138.","journal-title":"J Rheumatol"},{"key":"1856_CR108","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1002\/art.38851","volume":"66","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014;66:3255\u201364.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR109","doi-asserted-by":"crossref","unstructured":"Kivitz AJ, Mehta DP, Matzkies F, Mozaffarian A, Kunder R, Di Paolo J, et al. GS-9876, a novel, highly selective, SYK inhibitor in patients with active rheumatoid arthritis: safety, tolerability and efficacy results of a phase 2 study [abstract 2518]. Arthritis Rheumatol. 2018;70(Suppl. 9).","DOI":"10.1136\/annrheumdis-2019-eular.2144"},{"key":"1856_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074550","volume":"8","author":"AP Grammatikos","year":"2013","unstructured":"Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS\u00a0One. 2013;8: e74550.","journal-title":"PLoS\u00a0One"},{"key":"1856_CR111","doi-asserted-by":"publisher","first-page":"8145","DOI":"10.4049\/jimmunol.181.11.8145","volume":"181","author":"S Krishnan","year":"2008","unstructured":"Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol. 2008;181:8145\u201352.","journal-title":"J Immunol"},{"key":"1856_CR112","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1002\/art.38854","volume":"66","author":"SJ Fleischer","year":"2014","unstructured":"Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, D\u00f6rner T. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:3424\u201335.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR113","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","volume":"61","author":"VP Werth","year":"2022","unstructured":"Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022;61:2413\u201323.","journal-title":"Rheumatology (Oxford)"},{"key":"1856_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001490","volume":"6","author":"M Baker","year":"2020","unstructured":"Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020;6: e001490.","journal-title":"RMD Open"},{"key":"1856_CR115","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"1856_CR116","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.3390\/ijms222111595","volume":"22","author":"J Wang","year":"2021","unstructured":"Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism. Int J Mol Sci. 2021;22:11595.","journal-title":"Int J Mol Sci"},{"key":"1856_CR117","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1111\/ajt.14435","volume":"17","author":"SK Eskandari","year":"2017","unstructured":"Eskandari SK, Seelen MAJ, Lin G, Azzi JR. The immunoproteasome: an old player with a novel and emerging role in alloimmunity. Am J Transplant. 2017;17:3033\u20139.","journal-title":"Am J Transplant"},{"key":"1856_CR118","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12:232\u201340.","journal-title":"Nat Rev Nephrol"},{"key":"1856_CR119","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748\u201355.","journal-title":"Nat Med"},{"key":"1856_CR120","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.intimp.2011.11.019","volume":"12","author":"MM Seavey","year":"2012","unstructured":"Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12:257\u201370.","journal-title":"Int Immunopharmacol"},{"key":"1856_CR121","first-page":"393","volume":"28","author":"SW Lee","year":"2010","unstructured":"Lee SW, Kim BS. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB\/WF1 mice. Clin Exp Rheumatol. 2010;28:393\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"1856_CR122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.33333","volume":"64","author":"HT Ichikawa","year":"2012","unstructured":"Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheumatol. 2012;64:493\u2013503.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl","key":"1856_CR123","doi-asserted-by":"crossref","first-page":"A685","DOI":"10.1136\/annrheumdis-2018-eular.1100","volume":"77","author":"T Muchamuel","year":"2018","unstructured":"Muchamuel T, Anderl JL, Fan RA, Johnson HWB, Kirk CJ, Lowe ET. KZR-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE). Ann Rheum Dis. 2018;77(Suppl):A685.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756941","volume":"12","author":"T Walhelm","year":"2021","unstructured":"Walhelm T, Gunnarsson I, Heijke R, Leonard D, Trysberg E, Eriksson P, et al. Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study. Front Immunol. 2021;12: 756941.","journal-title":"Front Immunol"},{"key":"1856_CR125","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, K\u00fchl AA, Rubbert-Roth A, Lorenz HM, et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR126","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/rheumatology\/ket284","volume":"53","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Rupolo M, Michieli M, De Vita S. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (Oxford). 2014;53:381\u20132.","journal-title":"Rheumatology (Oxford)"},{"key":"1856_CR127","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0961203319896018","volume":"29","author":"A Segarra","year":"2020","unstructured":"Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020;29:118\u201325.","journal-title":"Lupus"},{"key":"1856_CR128","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0961203316686703","volume":"26","author":"H Zhang","year":"2017","unstructured":"Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26:952\u20138.","journal-title":"Lupus"},{"key":"1856_CR129","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/eji.201847492","volume":"48","author":"T Alexander","year":"2018","unstructured":"Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018;48:1573\u20139.","journal-title":"Eur J Immunol"},{"key":"1856_CR130","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","volume":"28","author":"T Ishii","year":"2018","unstructured":"Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28:986\u201392.","journal-title":"Mod Rheumatol"},{"key":"1856_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135081","volume":"10","author":"L Khodadadi","year":"2015","unstructured":"Khodadadi L, Cheng Q, Alexander T, Sercan-Alp \u00d6, Klotsche J, Radbruch A, et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB\/W F1 mice. PLoS\u00a0One. 2015;10: e0135081.","journal-title":"PLoS\u00a0One"},{"key":"1856_CR132","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1177\/0961203317691371","volume":"26","author":"C Sj\u00f6wall","year":"2017","unstructured":"Sj\u00f6wall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26:1333\u20138.","journal-title":"Lupus"},{"key":"1856_CR133","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1124\/dmd.120.000307","volume":"49","author":"Y Fang","year":"2021","unstructured":"Fang Y, Johnson H, Anderl JL, Muchamuel T, McMinn D, Morisseau C, et al. Role of epoxide hydrolases and cytochrome P450s on metabolism of KZR-616, a first-in-class selective inhibitor of the immunoproteasome. Drug Metab Dispos. 2021;49:810\u201321.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl. 1","key":"1856_CR134","first-page":"1482","volume":"79","author":"R Furie","year":"2020","unstructured":"Furie R, Parikh S, Maiquez A, Khan A, Moreno O, Soneira M, et al. Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first four cohorts of the MISSION study, an open-label phase 1b dose escalation trial. Ann Rheum Dis. 2020;79(Suppl. 1):1482.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR135","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14789450.2022.2142564","volume":"19","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Mateos MV, Vangsted AJ, Ramasamy K, Abildgaard N, Ho PJ, et al. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed\/refractory disease. Expert Rev Proteomics. 2022;19:235\u201346.","journal-title":"Expert Rev Proteomics"},{"key":"1856_CR136","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela ME, Zhang W, Man HW, Muller G, Khambatta G, Baculi F, et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018;61:535\u201342.","journal-title":"J Med Chem"},{"key":"1856_CR137","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","volume":"48","author":"LB John","year":"2011","unstructured":"John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. 2011;48:1272\u20138.","journal-title":"Mol Immunol"},{"key":"1856_CR138","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ajhg.2012.02.023","volume":"90","author":"CJ Lessard","year":"2012","unstructured":"Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90:648\u201360.","journal-title":"Am J Hum Genet"},{"key":"1856_CR139","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ejhg.2012.277","volume":"21","author":"C Wang","year":"2013","unstructured":"Wang C, Ahlford A, J\u00e4rvinen TM, Nordmark G, Eloranta ML, Gunnarsson I, et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur J Hum Genet. 2013;21:994\u20139.","journal-title":"Eur J Hum Genet"},{"key":"1856_CR140","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","volume":"77","author":"PH Schafer","year":"2018","unstructured":"Schafer PH, Ye Y, Wu L, Kosek J, Ringheim G, Yang Z, et al. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1516\u201323.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000445","volume":"8","author":"F Rivellese","year":"2021","unstructured":"Rivellese F, Manou-Stathopoulou S, Mauro D, Goldmann K, Pyne D, Rajakariar R, et al. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Lupus Sci Med. 2021;8: e000445.","journal-title":"Lupus Sci Med"},{"key":"1856_CR142","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/rheumatology\/kes227","volume":"51","author":"SW Lee","year":"2012","unstructured":"Lee SW, Park YB, Yang J, Park KH, Lee SK, Choi KH, et al. Attenuation of nephritis in lupus-prone mice by thalidomide. Rheumatology (Oxford). 2012;51:2131\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"1856_CR143","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/imm.12804","volume":"152","author":"EJ Kim","year":"2017","unstructured":"Kim EJ, Lee JG, Kim JY, Song SH, Joo DJ, Huh KH, et al. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. Immunology. 2017;152:628\u201337.","journal-title":"Immunology"},{"key":"1856_CR144","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/RHU.0000000000001160","volume":"27","author":"EFN Yuki","year":"2021","unstructured":"Yuki EFN, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, et al. Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol. 2021;27:248\u201359.","journal-title":"J Clin Rheumatol"},{"key":"1856_CR145","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol. 2017;3:980\u20138.","journal-title":"JAMA Oncol"},{"key":"1856_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000581","volume":"9","author":"RA Furie","year":"2022","unstructured":"Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9: e000581.","journal-title":"Lupus Sci Med"},{"key":"1856_CR147","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill JT, Werth VP, Furie R, van Vollenhoven R, D\u00f6rner T, Petronijevic M, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386:1034\u201345.","journal-title":"N Engl J Med"},{"key":"1856_CR148","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","volume":"81","author":"PE Lipsky","year":"2022","unstructured":"Lipsky PE, van Vollenhoven R, D\u00f6rner T, Werth VP, Merrill JT, Furie R, et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81:1136\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1856_CR149","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","volume":"81","author":"T P\u00e9rez-Jeldres","year":"2021","unstructured":"P\u00e9rez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985\u20131002.","journal-title":"Drugs"},{"key":"1856_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113341","volume":"153","author":"H Chen","year":"2022","unstructured":"Chen H, Wang J, Zhang C, Ding P, Tian S, Chen J, et al. Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomed Pharmacother. 2022;153: 113341.","journal-title":"Biomed Pharmacother"},{"key":"1856_CR151","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001261","volume":"6","author":"DS Strasser","year":"2020","unstructured":"Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, et al. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open. 2020;6: e001261.","journal-title":"RMD Open"},{"key":"1856_CR152","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbrc.2010.03.078","volume":"394","author":"S Ando","year":"2010","unstructured":"Ando S, Amano H, Amano E, Minowa K, Watanabe T, Nakano S, et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun. 2010;394:804\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"1856_CR153","first-page":"707","volume":"29","author":"H Okazaki","year":"2002","unstructured":"Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, et al. Effects of FTY720 in MRL-lpr\/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002;29:707\u201316.","journal-title":"J Rheumatol"},{"key":"1856_CR154","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/ki.2008.396","volume":"74","author":"SE Wenderfer","year":"2008","unstructured":"Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL\/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008;74:1319\u201326.","journal-title":"Kidney Int"},{"key":"1856_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5821589","volume":"2019","author":"K Sugahara","year":"2019","unstructured":"Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potently inhibits the progression of lupus nephritis in two murine SLE models. J Immunol Res. 2019;2019: 5821589.","journal-title":"J Immunol Res"},{"key":"1856_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193236","volume":"13","author":"KR Taylor Meadows","year":"2018","unstructured":"Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS\u00a0One. 2018;13: e0193236.","journal-title":"PLoS\u00a0One"},{"key":"1856_CR157","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2249.1997.d01-885.x","volume":"107","author":"S Suzuki","year":"1997","unstructured":"Suzuki S, Li XK, Shinomiya T, Enosawa S, Amemiya H, Amari M, et al. The in vivo induction of lymphocyte apoptosis in MRL-lpr\/lpr mice treated with FTY720. Clin Exp Immunol. 1997;107:103\u201311.","journal-title":"Clin Exp Immunol"},{"key":"1856_CR158","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbi.2018.03.009","volume":"70","author":"D Shi","year":"2018","unstructured":"Shi D, Tian T, Yao S, Cao K, Zhu X, Zhang M, et al. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus. Brain Behav Immun. 2018;70:293\u2013304.","journal-title":"Brain Behav Immun"},{"key":"1856_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02189","volume":"9","author":"EV Mike","year":"2018","unstructured":"Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, et al. Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol. 2018;9: 2189.","journal-title":"Front Immunol"},{"key":"1856_CR160","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1177\/0961203320966385","volume":"29","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S, et al. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study. Lupus. 2020;29:1902\u201313.","journal-title":"Lupus"},{"key":"1856_CR161","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000354","volume":"6","author":"V Hermann","year":"2019","unstructured":"Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6: e000354.","journal-title":"Lupus Sci Med"},{"key":"1856_CR162","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1856_CR163","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219\u201328.","journal-title":"N Engl J Med"},{"key":"1856_CR164","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/art.41900","volume":"74","author":"E Ginzler","year":"2022","unstructured":"Ginzler E, Guedes Barbosa LS, D\u2019Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, et al. Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 2022;74:112\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR165","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"1856_CR166","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319.","journal-title":"Lancet Rheumatol"},{"key":"1856_CR167","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81:951\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1856_CR168","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.kint.2022.05.033","volume":"102","author":"SV Parikh","year":"2022","unstructured":"Parikh SV, Malvar A, Song H, Shapiro J, Mejia-Vilet JM, Ayoub I, et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 2022;102(4):845\u201365.","journal-title":"Kidney Int"},{"key":"1856_CR169","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","volume":"20","author":"E Der","year":"2019","unstructured":"Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20:915\u201327.","journal-title":"Nat Immunol"},{"key":"1856_CR170","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/art.41508","volume":"73","author":"CC Mok","year":"2021","unstructured":"Mok CC, Mohan C. Urinary biomarkers in lupus nephritis: are we there yet? Arthritis Rheumatol. 2021;73:194\u20136.","journal-title":"Arthritis Rheumatol"},{"key":"1856_CR171","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2478\/rir-2020-0005","volume":"1","author":"CC Mok","year":"2020","unstructured":"Mok CC. The dawn of a new era of therapies in systemic lupus erythematosus. Rheumatol Immunol Res. 2020;1:31\u20137.","journal-title":"Rheumatol Immunol Res"},{"key":"1856_CR172","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01856-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:16:25Z","timestamp":1744715785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01856-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":172,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01856-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"27 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chi Chiu Mok has received speaker honoraria from GSK and Pfizer during the recent APLAR 2022 meeting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The sole author, Chi Chiu Mok, is responsible for the drafting of the manuscript and the literature search.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}